The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | The future of myeloma therapy and where the treatment landscape is moving
Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, briefly explains the future of myeloma treatment and where the landscape will move, drawing focus on novel immunotherapies such as CAR-T therapy and monoclonal antibodies, and the importance of using these therapies at an earlier stage and implementing early intervention. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
